INTS Earnings — Intensity Therapeutics, Inc. Common stock Post-ER Performance | BigEarnings
INTS — Intensity Therapeutics, Inc. Common stock
XNAS · Healthcare · Biotechnology
Price$4.39
Market Cap$11.9M
P/E—
52W Range$4.36 – $43.50
Next Earnings2026-08-06
About Intensity Therapeutics, Inc. Common stock
Intensity Therapeutics Inc is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.
